Radius Health Inc (NASDAQ:RDUS) has been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $38.29.

A number of equities research analysts have recently issued reports on RDUS shares. HC Wainwright started coverage on Radius Health in a report on Thursday, February 14th. They set a “neutral” rating and a $22.00 price objective for the company. Goldman Sachs Group upgraded Radius Health from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $26.00 to $38.00 in a report on Wednesday, May 29th. Cowen restated a “hold” rating on shares of Radius Health in a report on Wednesday, May 8th. BidaskClub cut Radius Health from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Finally, Zacks Investment Research upgraded Radius Health from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Monday, May 6th.

In related news, Director Debasish Roychowdhury sold 4,800 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total value of $106,320.00. Following the completion of the sale, the director now directly owns 5,500 shares in the company, valued at $121,825. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Joseph Francis Kelly purchased 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was bought at an average price of $21.43 per share, with a total value of $42,860.00. Following the completion of the purchase, the vice president now owns 5,000 shares of the company’s stock, valued at approximately $107,150. The disclosure for this purchase can be found here. Insiders own 4.00% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Radius Health by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after buying an additional 53,281 shares during the period. Norges Bank bought a new stake in shares of Radius Health in the fourth quarter valued at approximately $4,057,000. Rhumbline Advisers lifted its stake in Radius Health by 75.8% during the fourth quarter. Rhumbline Advisers now owns 61,939 shares of the biopharmaceutical company’s stock worth $1,021,000 after purchasing an additional 26,702 shares during the last quarter. BB Biotech AG lifted its stake in Radius Health by 1.8% during the fourth quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after purchasing an additional 120,000 shares during the last quarter. Finally, Knott David M lifted its stake in Radius Health by 251.2% during the fourth quarter. Knott David M now owns 77,269 shares of the biopharmaceutical company’s stock worth $1,274,000 after purchasing an additional 55,269 shares during the last quarter.

Shares of NASDAQ:RDUS opened at $21.81 on Tuesday. Radius Health has a 12-month low of $12.81 and a 12-month high of $31.92. The company has a market cap of $975.23 million, a PE ratio of -4.47 and a beta of 0.99. The company has a debt-to-equity ratio of 6.75, a current ratio of 5.16 and a quick ratio of 5.04.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.01. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. The company had revenue of $29.84 million during the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter in the previous year, the company posted ($1.11) earnings per share. The business’s revenue was up 105.1% on a year-over-year basis. As a group, sell-side analysts predict that Radius Health will post -3.51 earnings per share for the current fiscal year.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: What is a Derivative?

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.